Vancomycin, Serum, Peak

CPT: 80202
Print Share

Test Details

Synonyms

  • Vancocin®

Use

Use of intravenous vancomycin should be restricted to serious infections caused by susceptible staphylococci or other gram-positive bacteria when other antibiotics are ineffective or not tolerated.

Vancomycin is the drug of choice for serious infections caused by methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci (including S epidermidis). These infections include septicemia, endocarditis, osteomyelitis, pneumonia, lung abscesses, soft tissue infections, wound infections, and meningitis. Lumbar intrathecal or intraventricular administration may be required to treat meningitis.

Methicillin-resistant Staphylococcus epidermidis (and other coagulase-negative staphylococci) has become an important cause of infections associated with indwelling devices, including prosthetic heart valves, prosthetic hips, cerebrospinal fluid shunts, and intravenous (eg, Hickman) catheters. Vancomycin is the drug of choice for treatment of these infections. For prosthetic valve endocarditis caused by methicillin-resistant S epidermidis, intravenous vancomycin in combination with rifampin and gentamicin for two weeks, followed by vancomycin plus rifampin for an additional four weeks, has been recommended. Surgical intervention is frequently required.

Vancomycin is recommended for serious staphylococcal infections in patients who cannot receive (eg, due to hypersensitivity) or have failed to respond to penicillins and cephalosporins.

The combination of vancomycin with gentamicin or streptomycin (for susceptible strains) is the regimen of choice for enterococcal endocarditis in penicillin-allergic patients. Although vancomycin can be used to treat endocarditis caused by viridans streptococci in penicillin-allergic patients, first generation cephalosporins (eg, cefazolin, cephalothin, cephapirin) usually are preferred (unless there also is cephalosporin hypersensitivity).

When given intravenously, vancomycin is useful for prophylaxis of infective endocarditis in high-risk patients who are allergic to penicillin and who are undergoing dental or certain other surgical procedures.

Vancomycin is an alternative to first generation cephalosporins or antistaphylococcal penicillins for prophylaxis during certain surgical procedures (eg, cardiac valve replacement, total hip replacement) in patients allergic to penicillins and cephalosporins.

Vancomycin is the drug of choice for the uncommon pneumococcal infections that are resistant to penicillin G and for serious infections (eg, prosthetic valve endocarditis) caused by the penicillin-resistant JK strains of corynebacteria. It may be effective for Flavobacterium meningosepticum meningitis that is resistant to other antimicrobial agents.

When administered intravenously or intraperitoneally, this drug is useful in the management of peritonitis associated with continuous ambulatory peritoneal dialysis (CAPD). Gram-positive bacteria, particularly staphylococci, are the most common causative organisms of these infections.

Vancomycin is poorly absorbed from the gastrointestinal tract. Oral vancomycin is a drug of choice for antibiotic-associated pseudomembranous colitis (AAPMC) caused by Clostridium difficile, especially in seriously ill patients; however, oral metronidazole appears to be an effective and considerably less expensive alternative for mild-to-moderate disease and is frequently preferred in these patients.

Methodology

Immunoassay

Reference Interval

Therapeutic: 25.0−40.0 μg/mL

• Detection limit: 2.0 μg/mL; <2.0 μg/mL indicates none detected

Note: Peak levels drawn at 30 minutes are more variable and very dependent on consistent timing of collections. Differences of as little as 15 minutes in sampling time can result in a 10−15 μg/mL difference in measured vancomycin concentrations. It is important that consistency be maintained in the dosage interval and infusion period throughout the course of therapy for comparison of vancomycin concentrations to be valid. Peak levels collected at two hours are less variable.

Critical Value

Toxic: Peak vancomycin concentrations >80−100 μg/mL may be associated with ototoxicity. For patients on concomitant or sequential therapy with other oto- and/or nephrotoxic agents, vancomycin concentrations >30 μg/mL may be associated with nephrotoxicity. Trough vancomycin concentrations >20 μg/mL may be associated with the onset of nephrotoxicity.

Additional Information

Following slow intravenous infusion of 1 g, peak serum concentrations of 25.0−40.0 μg/mL and trough levels of 10.0−15.0 μg/mL are observed. Approximately 55% of circulating vancomycin is bound to plasma proteins. The steady-state volumes of distribution in adult and pediatric subjects range from 0.39−0.92 L/kg and 0.45−0.97 L/kg, respectively. Adequate concentrations of drug are attained in pleural, ascitic, pericardial, and synovial fluids. Low levels are found in bile; however, in patients with normal renal function, high concentrations are attained in urine. Vancomycin does not penetrate the uninflamed meninges, but therapeutic levels may be attained in cerebrospinal fluid in the presence of meningitis. Lumbar intrathecal or intraventricular administration may be necessary in some patients. Information on concentrations in human tissues is very limited. Potentially therapeutic concentrations of vancomycin have been observed in peritoneal dialysis fluid after intravenous administration in patients undergoing continuous ambulatory peritoneal dialysis.

Vancomycin is eliminated by the kidneys, primarily by glomerular filtration; 80% to 90% of a dose appears in the urine of healthy subjects as unchanged drug within 24 hours. The usual elimination half-life in adults with normal renal function ranges from three to nine hours (mean, six hours). In one study, longer elimination half-lives were reported for men older than 60 years compared to men between 20 and 26 years (mean half-lives, 12.1 and 7.2 hours, respectively). Elimination half-lives are 5.9 to 9.8 hours in newborns, 4.1 hours in older infants, and 2.2 to 4 hours in children. In anuric patients, the half-life may be prolonged to eight or nine days. Dosage reductions are necessary in patients with renal insufficiency. Although it has been reported that elimination is prolonged in patients with impaired hepatic function, the consensus is that nonrenal elimination is minor and dosage reductions are unnecessary.

Specimen Requirements

Specimen

Serum or plasma

Volume

1 mL

Minimum Volume

0.3 mL

Container

Red-top tube or green-top (heparin) tube. Do not use a gel-barrier tube. The use of gel-barrier tubes is not recommended due to slow absorption of the drug by the gel. Depending on the specimen volume and storage time, the decrease in drug level due to absorption may be clinically significant.

Collection

Transfer separated serum or plasma to a plastic transport tube. Both peak and trough concentrations should be monitored. The trough sample is drawn immediately prior to the next dose.

Storage Instructions

Refrigerate

Stability Requirements

Temperature

Period

Room temperature

3 days

Refrigerated

14 days

Frozen

14 days

Freeze/thaw cycles

Stable x3

Causes for Rejection

Gel-barrier tube; hemolysis; lipemia; gross bacterial contamination

Clinical Information

Special Instructions

Peak levels should be ordered using test 070327. Trough levels should be ordered using test 070328. Peak and trough levels may be ordered together as a profile on the same request form using test 717314. Please label tubes appropriately as “peak” and “trough.”

References

American Medical Association, Division of Drugs and Toxicology. Drug Evaluations Subscription. Chicago, Ill: AMA, Spring 1990.
Brunton L, Lazo J, Parker K. Goodman & Gillman's The Pharmacological Basis of Therapeutics. 11th ed. New York, NY: McGraw-Hill; 2006.
Burtis CA, Ashwood CR, Bruns DE, eds. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. St Louis, Mo: Elsevier Saunders; 2006.
Dart RC, Caravati EM, McGuigan MA, et al. Medical Toxicology. Philadelphia, Pa: Lippincott Williams & Wilkins;2006.
Mosby's Drug Consult 17th ed. St Louis, Mo: Elsevier Saunders; 2007.
Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009 Jan 1; 66(1):82-98. 19106348

LOINC® Map

Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
070327 Vancomycin Peak, Serum 4090-7 070333 Vancomycin Peak, Serum ug/mL 4090-7
Reflex Table for Vancomycin Peak, Serum
Order Code Order Name Result Code Result Name UofM Result LOINC
Reflex 1 007000 See below: 007000 See below: N/A

For Providers

Please login to order a test.

 

© 2017  Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2017, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf